Sovaldi – Record Breaking Sales More Than Doubled Forecast!

Gilead Sciences Inc has seen record-breaking sales of its new Hepatitis C drug, Sovaldi, with over $2 Billion in the first quarter- the highest EVER for a new medicine. Read more here. (Source: Deena Beasley, Reuters, 4/22/14).

You might also be interested in:

Analyst: Insurance Strategy Pulls Down Drug Prices September 6, 2018
eDossier System to Offer hēRo3 Model Integration November 8, 2018
PAI and BresMed Join Forces to Support Expanded Use of More… July 22, 2019
Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026 August 19, 2019
The Global Use of Medicine in 2019 and Outlook to 2023 January 29, 2019
Reuters: CVS Adds Teva, Lilly Migraine Drugs February 1, 2019
Novartis Floats Discounts for SMA Therapy May 16, 2019